OctoPlus, the drug delivery and development company, announced that it has obtained full rights for the development of all applications of OP-145 through expansion of the license agreement. The product is currently in clinical development for the treatment of chronic middle ear infection, and also showing potential in other indications such as sinusitis and disorders caused by the formation of bacterial biofilms. DrugNewswire (http://www.drugnewswire.com/3077/)